[Code of Federal Regulations]
[Title 21, Volume 7]
[Revised as of April 1, 2008]
From the U.S. Government Printing Office via GPO Access
[CITE: 21CFR660.25]
[Page 122-123]
TITLE 21--FOOD AND DRUGS
CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN
SERVICES (CONTINUED)
PART 660_ADDITIONAL STANDARDS FOR DIAGNOSTIC SUBSTANCES FOR LABORATORY TESTS--
Subpart C_Blood Grouping Reagent
Sec. 660.25 Potency tests without reference preparations.
Products for which Reference Blood Grouping Reagents are not
available shall be tested for potency by a method approved by the
Director, Center for Biologics Evaluation and Research.
(a) Potency requirements. Blood Grouping Reagents recommended for
the test tube methods, including the indirect antiglobulin tests, shall
have the following potency titer values, unless other values are
approved by the Director, Center for Biologics Evaluation and Research.
(1) For Anti-K, Anti-k, Anti-Jk a, Anti-Fy a,
Anti-C w, at least 1+ reaction with a 1:8 dilution of the
reagent.
(2) For Anti-S, Anti-s, Anti-P1, Anti-M, Anti-I, Anti-e
(saline), Anti-c (saline), and Anti-A1, at least 1+ reaction
with a 1:4 dilution of the reagent.
(3) For Anti-U, Anti-Kp\a\, Anti-Kp\b\, Anti-Js\a\, Anti-Js\b\,
Anti-Fy\b\, Anti-N, Anti-Le\a\, Anti-Le\b\, Anti-Lu\a\, Anti-Lu\b\,
Anti-Di\a\, Anti-M\g\, Anti-Jk\b\, Anti-Co\b\, Anti-Wr\a\, and Anti-
Xg\a\, at least 2+ reaction with undiluted reagent.
(b) Products recommended for slide tests or microplate techniques.
Blood Grouping Reagent recommended for slide test methods or microplate
techniques shall
[[Page 123]]
produce clearly positive macroscopic results when both undiluted reagent
and reagent diluted with an equal volume of diluent are tested by all
methods recommended in the manufacturer's package insert using red blood
cells showing heterozygous or diminished expression of the corresponding
antigen. The dilution shall be made with an equal volume of compatible
serum or approved diluent.
(c) Products recomended for use in an automated system. The
manufacturer of Blood Grouping Reagent that is recommended for use in an
automated system shall demonstrate that its product when used both
undiluted and diluted with an equal volume of diluent satisfactorily
performs when tested with cells representing heterozygous or diminished
expression of the corresponding antigen.
[53 FR 12764, Apr. 19, 1988, as amended at 67 FR 9587, Mar. 4, 2002; 70
FR 14985, Mar. 24, 2005]